Category Odds Ratio (95% CI) p value
Age (older        vs. younger) 1.01 (1.00-1.01) <0.001
Year of step-down date (later vs. earlier) 0.89 (0.83-0.95) <0.001
No rhinitis diagnosis and/or drugs 1.00 0.001
       vs. rhinitis diagnosis and/or drugs 1.18 (1.07-1.30)  
No GERD diagnosis and/or drugs 1.00 <0.001
       vs. GERD diagnosis and/or drugs 1.27 (1.13-1.42)  
No acetaminophen prescription 1.00 <0.001
       vs. yes acetaminophen prescription 1.20 (1.07-1.34)  
0-1 SABA prescriptions/years 1.00 <0.001
       vs. 2-3/years 1.17 (1.02-1.34)  
       vs. 4-6/years 1.27 (1.11-1.46)  
       vs. ≥7/years 1.46 (1.29-1.66)  
ICS dose 1-100 µg/day 1.00 0.031
       vs. 101-200 µg/day 1.10 (0.92-1.31)  
       vs. 201-400 µg/day 0.995 (0.84-1.18)  
       vs. 401-800 µg/day 1.16 (0.99-1.37)  
       vs. >800 µg/day 1.21 (1.02-1.43)  
0-3 primary care consultations/years 1.00 <0.001
       vs. 4-5/years 1.41 (1.20-1.65)  
       vs. 6-8/years 1.61 (1.39-1.87)  
       vs. 9-13/years 1.83 (1.58-2.12)  
       vs. ≥ 14/years 1.92 (1.65-2.24)  

*See text for definition.
GERD: Gastroesophageal Reflux Disease; ICS: Inhaled Corticosteroid; LABA: Long-Acting β-Agonist; SABA: Short-Acting β-Agonist
Table 5: Demographic and baseline factors predictive of loss of asthma control during the year after ICS dose step-down for all patients in the ICS/LABA cohorts who met the composite database measure of no loss of asthma control* during the baseline year (n=11,338): A multivariate model.
Goto home»